Verbatim response from ChatGPT
Short answer
- Many people see noticeable weight loss within weeks and substantial loss over months, but how fast and how much varies a lot by drug, dose, starting weight, and behavior.
- With GLP‑1/GIP drugs you usually need ongoing treatment (or very intensive lifestyle/behavior changes) to keep the weight off — stopping the drug commonly leads to regain.
What the clinical trials show (typical ranges)
- Semaglutide for obesity (Wegovy® 2.4 mg weekly): average ~10–15% body‑weight loss after ~68 weeks in trials (STEP program). Most people lose steadily over the first 6–12 months.
- Semaglutide for diabetes (Ozempic® 0.5–1.0 mg weekly): smaller average loss (~4–6%) because dose/setting differ.
- Tirzepatide (Mounjaro® for diabetes; Zepbound® for weight): larger average losses in obesity trials — roughly 15–21% at ~72 weeks depending on dose (higher doses -> more weight loss).
- Timeline: you commonly see early losses within the first 4–12 weeks, a larger chunk within the first 3–6 months, and continued loss up to about 12–18 months in trials.
Why people differ
- Starting weight and body composition, dose achieved, how well you tolerate the drug (GI side effects often limit dose), how strictly you change eating/exercise habits, other medicines or conditions, and genetics all affect results. Individual responses range from very little to >20% body‑weight loss.
Sustainability
- GLP‑1/GIP drugs change appetite, satiety and some metabolic parameters while you take them; they do not “rewire” every biological driver of weight permanently. In trial extensions and withdrawal studies, many people regained much of the lost weight when the drug was stopped.
- Best chance to sustain loss: continue medication as recommended by your clinician AND work on long‑term behavioral changes (structured nutrition plan, physical activity, sleep, stress management, and often behavioral counseling). Some people stay on these medicines long term under medical supervision.
Risks and monitoring
- Common: nausea, vomiting, diarrhea, constipation, early satiety.
- Less common/serious: gallbladder disease, pancreatitis (rare), increases in heart rate, and there are contraindications (personal or family history of certain thyroid cancers, MEN2). You need baseline and periodic follow‑up with a prescriber.
What to do next / Questions to ask your clinician
- Which drug and dose is appropriate for me (Wegovy vs Ozempic vs Mounjaro vs Zepbound)?
- What weight loss target is reasonable in 3, 6, and 12 months?
- How long should I expect to take it? If I stop, what’s the plan to prevent regain?
- How will side effects be managed? What monitoring is needed?
Brands/services to consider (talk to your clinician)
- Wegovy® (semaglutide 2.4 mg) — approved specifically for chronic weight management and backed by large obesity trials.
- Zepbound® (tirzepatide for weight) — newer, showed very large average weight loss in obesity trials.
- Mounjaro® (tirzepatide for diabetes) and Ozempic® (semaglutide for diabetes) — used for diabetes but often discussed with clinicians for weight effects (doses/indications differ).
- See an obesity medicine specialist or a multidisciplinary weight‑loss clinic (look for clinicians certified by the American Board of Obesity Medicine or centers that offer medical, nutritional, and behavioral support) — combining medication with structured support gives better long‑term outcomes.
Bottom line You can often lose substantial weight on GLP‑1/GIP medicines over months (commonly 10–20% in obesity trials for the most effective agents/doses), but long‑term maintenance usually requires ongoing therapy or intensive lifestyle/behavioral strategies. Discuss risks, expected timeline, and a stopping/maintenance plan with a prescriber before starting.
If you want, tell me your age, current weight/height, medical conditions and whether you have a preference between semaglutide or tirzepatide — I can give a more personalized expectation and a list of questions to bring to your doctor.